These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 31786833)

  • 41. RAS-expanded Mutations and HER2 Expression in Metastatic Colorectal Cancer: A New Step of Precision Medicine.
    Valentini AM; Cavalcanti E; Di Maggio M; Caruso ML
    Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):539-544. PubMed ID: 30199395
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The RAS paradox of the EGFR-targeted therapy in colorectal cancer].
    Tímár J; Láng I
    Magy Onkol; 2008 Jun; 52(2):185-91. PubMed ID: 18640895
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
    Price T; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Guan X; Peeters M
    Eur J Cancer; 2016 Nov; 68():51-59. PubMed ID: 27716478
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeted therapy in first line treatment of RAS wild type colorectal cancer.
    Formica V; Roselli M
    World J Gastroenterol; 2015 Mar; 21(10):2871-4. PubMed ID: 25780283
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
    Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
    Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeted Therapy for Colorectal Cancer.
    Sakata S; Larson DW
    Surg Oncol Clin N Am; 2022 Apr; 31(2):255-264. PubMed ID: 35351276
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
    Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
    PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
    Scartozzi M; Giampieri R; Maccaroni E; Mandolesi A; Giustini L; Silva R; Zaniboni A; Biscotti T; Biagetti S; Galizia E; Loupakis F; Falcone A; Bearzi I; Cascinu S
    Ann Oncol; 2012 Jul; 23(7):1706-12. PubMed ID: 22112971
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.
    Garm Spindler KL; Pallisgaard N; Rasmussen AA; Lindebjerg J; Andersen RF; Crüger D; Jakobsen A
    Ann Oncol; 2009 May; 20(5):879-84. PubMed ID: 19179548
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
    Stiegelbauer V; Perakis S; Deutsch A; Ling H; Gerger A; Pichler M
    World J Gastroenterol; 2014 Sep; 20(33):11727-35. PubMed ID: 25206276
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients.
    Bonin S; Donada M; Bussolati G; Nardon E; Annaratone L; Pichler M; Chiaravalli AM; Capella C; Hoefler G; Stanta G
    Tumour Biol; 2016 Jun; 37(6):7295-303. PubMed ID: 26666825
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy.
    Graham CN; Maglinte GA; Schwartzberg LS; Price TJ; Knox HN; Hechmati G; Hjelmgren J; Barber B; Fakih MG
    Clin Ther; 2016 Jun; 38(6):1376-1391. PubMed ID: 27085587
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
    García-Alfonso P; Grande E; Polo E; Afonso R; Reina JJ; Jorge M; Campos JM; Martínez V; Angeles C; Montagut C
    Angiogenesis; 2014 Oct; 17(4):805-21. PubMed ID: 24793846
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cetuximab in the treatment of patients with colorectal cancer.
    Garrett CR; Eng C
    Expert Opin Biol Ther; 2011 Jul; 11(7):937-49. PubMed ID: 21557708
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRC.
    McGregor M; Price TJ
    Future Oncol; 2018 Oct; 14(24):2437-2459. PubMed ID: 29737864
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
    Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
    Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
    [TBL] [Abstract][Full Text] [Related]  

  • 57. miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial.
    Anandappa G; Lampis A; Cunningham D; Khan KH; Kouvelakis K; Vlachogiannis G; Hedayat S; Tunariu N; Rao S; Watkins D; Starling N; Braconi C; Darvish-Damavandi M; Lote H; Thomas J; Peckitt C; Kalaitzaki R; Khan N; Fotiadis N; Rugge M; Begum R; Rana I; Bryant A; Hahne JC; Chau I; Fassan M; Valeri N
    Clin Cancer Res; 2019 Jul; 25(13):3830-3838. PubMed ID: 30952636
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
    Fornaro L; Lonardi S; Masi G; Loupakis F; Bergamo F; Salvatore L; Cremolini C; Schirripa M; Vivaldi C; Aprile G; Zaniboni A; Bracarda S; Fontanini G; Sensi E; Lupi C; Morvillo M; Zagonel V; Falcone A
    Ann Oncol; 2013 Aug; 24(8):2062-7. PubMed ID: 23666916
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
    Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
    Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
    [TBL] [Abstract][Full Text] [Related]  

  • 60. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
    Normanno N; Esposito Abate R; Lambiase M; Forgione L; Cardone C; Iannaccone A; Sacco A; Rachiglio AM; Martinelli E; Rizzi D; Pisconti S; Biglietto M; Bordonaro R; Troiani T; Latiano TP; Giuliani F; Leo S; Rinaldi A; Maiello E; Ciardiello F;
    Ann Oncol; 2018 Jan; 29(1):112-118. PubMed ID: 28950295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.